Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 10/20 | 0.73 |
| ▸ | MMP9 | P14780 | 10/20 | 0.73 |
| ▸ | MMP8 | P22894 | 9/20 | 0.73 |
| ▸ | MMP1 | P03956 | 10/20 | 0.58 |
| ▸ | FCER2 | P06734 | 2/20 | 0.57 |
| ▸ | MMP3 | P08254 | 3/20 | 0.56 |
| ▸ | MMP7 | P09237 | 2/20 | 0.56 |
| ▸ | CCR1 | P32246 | 1/20 | 0.52 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | CPA1 | P15085 | 1/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5558802 | 0.88 | MMP2 (0.81) | MMP2MMP9MMP8MMP1FCER2 | |
| SCHEMBL5556655 | 0.88 | MMP2 (0.81) | MMP2MMP9MMP8MMP1FCER2 | |
| SCHEMBL5558806 | 0.88 | MMP2 (0.81) | MMP2MMP9MMP8MMP1FCER2 | |
| SCHEMBL5556662 | 0.88 | MMP2 (0.81) | MMP2MMP9MMP8MMP1FCER2 | |
| SCHEMBL7612909 | 0.88 | MMP1 (0.71) | MMP2MMP9MMP8MMP1FCER2 | |
| SCHEMBL5552911 | 0.84 | MMP2 (1.00) | MMP2MMP9MMP8MMP1FCER2 | |
| SCHEMBL5552919 | 0.84 | MMP2 (1.00) | MMP2MMP9MMP8MMP1FCER2 | |
| SCHEMBL5556836 | 0.84 | MMP2 (1.00) | MMP2MMP9MMP8MMP1FCER2 | |
| SCHEMBL4670160 | 0.83 | MMP1 (0.78) | MMP2MMP9MMP8MMP1MMP3 | |
| SCHEMBL6434829 | 0.82 | MMP2 (0.69) | MMP2MMP9MMP8MMP1FCER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020607-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2005-01-27 | — | — | US | disclosed |
| EP-0558648-B1 | IMPROVED MATRIX METALLOPROTEASE INHIBITORS | GALARDY RICHARD E (US) | 2004-04-28 | — | — | EP | disclosed |
| EP-1366765-A1 | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing | WARNER-LAMBERT COMPANY LLC (US) | 2003-12-03 | — | — | EP | disclosed |
| EP-1047450-B1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER LAMBERT CO (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2002-04-25 | — | — | US | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1063991-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-0663823-B1 | INHIBITION OF ANGIOGENESIS BY SYNTHETIC MATRIX METALLOPROTEASE INHIBITORS | GLYCOMED INC (US) | 2000-11-22 | — | — | EP | disclosed |
| EP-1047450-A1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 2000-11-02 | — | — | EP | disclosed |
| US-6133304-A | TREATING FIBROSIS, VENTRICULAR DILATION, AND/OR HEART FAILURE IN A MAMMAL BY ADMINISTERING AN ANTIFIBROTIC AMOUNT OF A MIXTURE OF AN ANGIOTENSIN-CONVERTING ENZYME(ACE) INHIBITOR AND AT LEAST ONE MATRIX METALLOPROTEINASE(MMP) INHIBITOR | WARNER-LAMBERT COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0558635-A4 | IMPROVED MATRIX METALLOPROTEASE INHIBITORS | — | 1993-11-24 | — | — | EP | disclosed |
| EP-0558648-A4 | IMPROVED MATRIX METALLOPROTEASE INHIBITORS | — | 1993-11-24 | — | — | EP | disclosed |
| EP-0558648-A1 | IMPROVED MATRIX METALLOPROTEASE INHIBITORS | GALARDY, Richard, E. (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558635-A1 | IMPROVED MATRIX METALLOPROTEASE INHIBITORS. | GLYCOMED INC (US) | 1993-09-08 | — | — | EP | disclosed |
| US-5239078-A | Collagenase enzyme inhibitors | GLYCOMED INCORPORATED (US) | 1993-08-24 | — | — | US | disclosed |
| US-5189178-A | Preventing protein destruction | GALARDY RICHARD E (US) | 1993-02-23 | — | — | US | disclosed |
| US-5183900-A | Matrix metalloprotease inhibitors | GALARDY RICHARD E (US) | 1993-02-02 | — | — | US | disclosed |
| WO-1992009563-A1 | IMPROVED MATRIX METALLOPROTEASE INHIBITORS | GLYCOMED, INC. (US) | 1992-06-11 | — | — | WO | disclosed |
| WO-1992009556-A1 | IMPROVED MATRIX METALLOPROTEASE INHIBITORS | GALARDY RICHARD E (US) | 1992-06-11 | — | — | WO | disclosed |
| US-5114953-A | Peptides | UNIVERSITY OF FLORIDA (US) | 1992-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020607-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP2 19/4885MMP9 1/4885MMP8 29/4885 |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP2 19/4885MMP9 1/4885MMP8 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.